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Abstract
a-galactosylceramide (a-GalCer) is the prototypical lipid ligand for invariant NKT cells. Recent studies have proposed that a-
GalCer is an effective adjuvant in vaccination against a range of immune challenges, however its mechanism of action has
not been completely elucidated. A variety of delivery methods have been examined including pulsing dendritic cells with a-
GalCer to optimize the potential of a-GalCer. These methods are currently being used in a variety of clinical trials in patients
with advanced cancer but cannot be used in the context of vaccine development against pathogens due to their
complexity. Using a simple delivery method, we evaluated a-GalCer adjuvant properties, using the mouse model for
cytomegalovirus (MCMV). We measured several key parameters of the immune response to MCMV, including inflammation,
effector, and central memory CD8
+ T cell responses. We found that a-GalCer injection at the time of the infection decreases
viral titers, alters the kinetics of the inflammatory response, and promotes both increased frequencies and numbers of virus-
specific memory CD8
+ T cells. Overall, our data suggest that iNKT cell activation by a-GalCer promotes the development of
long-term protective immunity through increased fitness of central memory CD8
+ T cells, as a consequence of reduced
inflammation.
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Introduction
Adjuvants are mediators that enhance the natural immune
response. Two vaccine adjuvants are approved in the United
States for prophylactic vaccination; aluminum adjuvants (Alum)
and monophosphoryl lipid A (MPLA). Alum is currently used to
boost immune responses in conjunction with a number of vaccines
including those against hepatitis A, tetanus, and influenza, while
MPLA (a derivative of Salmonella minnesota LPS) is currently
used as an adjuvant for the human papillomavirus vaccine [1]. A
major downfall of these adjuvants, however, is that they do not
effectively promote protective cell-mediated immunity [2]. Cell-
mediated immunity marked by robust CD8
+ T cell responses is
critical for developing efficacious vaccines against diseases such as
malaria and human immunodeficiency virus. Previous attempts to
generate vaccines against a variety of diseases including HIV,
malaria and tuberculosis have been mostly unsuccessful. To
prevent these infections, it is believed that vaccines will need to
induce the generation of an adequate and strong CD8
+ T cell
memory response [3]. Immunological memory is essential for
protection from previously encountered pathogens and can limit
reactivation of existing latent infections [4]. CD8
+ memory T cells
respond efficiently and robustly, mounting a specific response
much faster than their naı ¨ve counterpart [5]. Memory T cells
show directed cytokine production, long term survival, and an
ability to self renew. Recently, using a variety of cell surface
markers, several groups have been able to distinguish memory
precursor effector cells (MPECs) as CD8
+ T cells that have a
potential to survive and become long-lived memory CD8
+ T cells
from short-lived effector cells (SLECs) [6,7].
Recent studies have evaluated a-Galactosylceramide (a-GalCer)
as a potential adjuvant due to its ability to induce the activation of
a variety of immune cells [8,9,10,11,12], although in at least one
case a-GalCer treatment fails to control viral replication [13]. a-
GalCer is the powerful iNKT agonist and is presented by the
nonclassical MHC molecule CD1d in both mice and humans [14].
a-GalCer administrated with a variety of vaccines increases their
efficacy and its action is mediated in part by IFN-c [15].
In the case of CD8
+ T cell responses, treatment with a-GalCer
has been shown to increase the CD8
+ memory T cell population in
the context of an influenza vaccine through upregulation of the
prosurvival gene Bcl-2, in mice [16]. The evidence that a-GalCer
has an effect on long term CD8
+ T cell memory is limited in other
viral systems and its mechanism of action on the generation of
MPECs versus SLECs is unknown. We therefore sought to
determine the role and mechanism of a-GalCer during murine
cytomegalovirus (MCMV) infection. MCMV is the model for the
human b-herpesvirus HCMV and presents with pathologically
similar features to the human form of the virus [17]. CMV induces
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cytolytic CD8
+ T cell activity [18,19]. Following acute infection,
the virus migrates from the primary organs of infection to the
salivary glands in both mice and humans where it remains for up
to a few months [20,21]. After this point, the virus becomes
virtually undetectable in both systems. This latent form however,
can reactivate upon an immunocompromised state and pose
serious health risks such as retinitis, colitis, or liver damage. An
optimal CD8
+ memory T cell response is therefore critical to
maintaining latency of the virus.
Here, we show that a single a-GalCer injection at the time of
the infection decreases viral titers, alters the kinetics of the
inflammatory response, and promotes both increased frequencies
and numbers of virus-specific memory CD8
+ T cells. We present a
model in which adequate iNKT cell activation could potentially
promote long-term immunity and help prevent viral reactivation.
Results
a-GalCer treatment interferes with MCMV induced
cytokine production
a-GalCer treatment results in rapid production of IFN-c and
IL-4, as well as other cytokines in the serum at 4 hours post-
treatment as a consequence of direct iNKT cell activation (Fig. 1
and data not shown). MCMV replication promotes production of
pro-inflammatory cytokines and chemokines (IL-12p70, IFN-c,
TNF-a, MIP-1a, IL-6, and MCP-1), which peak between 24 and
40 hours post-infection in the blood depending on the cellular
source of the cytokine [22]. At 38 hours post-infection with no a-
GalCer treatment, IFN-c reaches its peak and IL-12p70 is
detectable in the blood (Fig. 2). However, IL-12p70 is absent
and serum IFN-c is severely diminished when a-GalCer is
administered in conjunction with MCMV infection (Fig. 2).
Similarly, TNF-a, MCP-1, IL-6, and MIP-1a responses are all
decreased at this time point after a-GalCer treatment (Fig. 2).
Notably, IL-10, IL-4, IL-21, IL-17A, GM-CSF are not detected
under either of the tested conditions. Thus a-GalCer treatment
alters the kinetics of the normal MCMV inflammatory cytokine
response.
Viral titers are severely diminished at 48 hours after a-
GalCer treatment
One of the early studies has shown that a-GalCer administra-
tion inhibits viral replication in a hepatitis B virus-transgenic
model [23]. Within 24 hours of a-GalCer injection, IFN-c and
IFNa/b are detected in the liver of HBV transgenic mice and HBV replication is abolished. a-GalCer treatment has also been
shown to affect viral titers for several models of viral infections
[24,25,26,27] including MCMV [28]. Based on these previous
studies with a-GalCer, we hypothesized that a-GalCer induced
cytokine production at early time points and direct anti-viral
effects would result in decreased viral titers at 48 hours post-
treatment. MCMV titers in homogenates of spleen and liver
samples from MCMV infected and MCMV+a-GalCer groups
were determined by standard plaque assay. In agreement with
others [28], we found that MCMV titers were significantly
reduced in mice treated with a-GalCer in both spleen and liver
(Fig. 3). Thus the availability of antigen for MCMV specific CD8
+
T cells is decreased under these conditions.
CD8
+ T cell effector numbers are not decreased by a-
GalCer
CD8
+ T cells are major contributors in the acute response to
MCMV infection. Despite encoding for approximately 170
proteins and a large number of potential antigens, only several
Figure 1. a-GalCer promotes Th1 and Th2 cytokine production
by 4 hours. IFN-c (A) and IL-4 (B) levels were determined at 4 hours in
blood serum after a-GalCer treatment and/or MCMV infection by ELISA.
*p-value,0.005.
doi:10.1371/journal.pone.0037991.g001
Figure 2. a-GalCer treatment modulates MCMV-dependent
cytokine profile. Blood sera were collected at 38 hours post-infection
and cytokines measured using the BD CBA Flex Kit. Cytokines not
detected under any condition tested: IL-10, IL-4, IL-21, IL-17A, GM-CSF.
*p-value#0.002.
doi:10.1371/journal.pone.0037991.g002
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including M38, M139, M45, and M57 [29]. CD8
+ T cells specific
to M38 and M139 are connected with a population referred to as
inflationary cells [30]. In contrast, CD8
+ T cells specific for other
MCMV epitopes (non-inflationary) have been shown to differen-
tiate to a classical central memory phenotype [31]. Here, we
focused on classical memory CD8
+ T cells specific for M45 and
M57, which expand during acute infection but have also been
associated with long-term protection against MCMV [29]. We first
examined the effect of a-GalCer on the effector CD8
+ T cell
response. To do this, the spleens and livers of mice infected with
MCMV with and without a-GalCer treatment were evaluated at
day 7 post-infection. We utilized a combination of tetramers
loaded with M45 or M57 to identify MCMV specific CD8
+ T cells
(representative staining shown in Fig. S1A and B). Despite
observing a lower frequency of tetramer positive cells in these
organs, there was no overall difference in absolute numbers of
MCMV-specific effector CD8
+ T cells at day 7 in the spleen (Fig. 4)
while there was a slight increase in the liver. To further verify that
this population maintained its effector status, tetramer positive
cells were characterized using the classical markers KLRG1 and
CD62L (Fig. S1 C and D). Most tetramer positive cells expressed
high levels of KLRG1 and low levels of CD62L, which are
indicative of an effector population. Thus, although a-GalCer
administration during MCMV infection induces a decreased viral
titer the number of antigen specific effector CD8
+ T cells is not
significantly affected.
Central memory frequency and absolute numbers are
increased with a-GalCer
It is well known that the early inflammatory milieu dictates the
rate at which CD8
+ T cells acquire memory characteristics [6,32].
Excess of inflammatory cytokines such as IL-12 and IFN-a has
been shown to promote CD8
+ T cell differentiation leading to a
decrease of central CD8
+ memory T cells [6,33,34]. The
magnitude of infection, strength of stimulus, and antigen levels
can also influence the rate of memory T cell differentiation
[35,36]. Due to the change in the inflammatory cytokine profile
and the lower viral titer observed after a-GalCer treatment, we
hypothesized that a-GalCer may influence effector versus memory
cell fate decision. To define the MCMV-specific central memory
response, mice were infected with MCMV with and without a-
GalCer treatment and sacrificed 9-weeks later. As anticipated, the
frequency of MCMV-specific (defined as M45 tetramer positive or
M57 tetramer positive) CD8
+ T cells drastically decreased since
the day 7 time point, as a result of contraction following the acute
expansion in response to antigen recognition (Fig. 5A, B).
Interestingly, the absolute number of MCMV-specific CD8
+ T
cells in both spleen and liver were comparable between the
MCMV+a-GalCer and MCMV control groups (Fig. 5C, D). We
further characterized these cells using specific markers for the
central memory population. We defined this population as
tetramer positive cells that expressed CD62L, CD127, and
CD44, but are mostly negative or low for KLRG1 (Fig. S2).
Using this phenotype we show that the frequencies of central
memory CD8
+ T cells in MCMV+a-GalCer treated spleen and
liver are significantly higher than the frequencies of central
memory cells from MCMV infected mice (Fig. 6A, B). Impor-
tantly, this phenomenon translates to the absolute number of
central memory cells (Fig. 6C, D). These results show that a single
a-GalCer treatment at the time of infection promotes accumula-
tion of CD8
+ central memory T cells specific for MCMV antigens.
Discussion
Many viruses are controlled by effector CD8
+ T cells as
antibodies are not effective against intracellular pathogens. After
disease resolution, these effector cells contract leaving a long-lived
central memory population. This CD8
+ T cell memory population
is maintained and expands to prevent infection upon subsequent
exposure as well as control chronic or latent infections. Vaccina-
tion strategies that elicit an optimal CD8
+ T cell response directed
against intracellular pathogens are actively pursued [37]. Adju-
vants are among the factors governing the regulation and
differentiation of the CD8
+ T cell memory response. Here we
tested the potential of a-GalCer as an adjuvant during MCMV
infection. iNKT cells can respond within minutes to specific
glycolipids such as a-GalCer [14,38] and have the capacity to
produce high quantities of both Th1 and Th2 cytokines. This
cytokine storm can crosstalk with NK cells or, in conjunction with
Figure 3. a-GalCer treatment decreases viral titers in the spleen
and liver. Spleen (A) and liver (B) were harvested at 48 hr post-
infection and MCMV titers were determined by standard plaque assay.
*p-value#0.007.
doi:10.1371/journal.pone.0037991.g003
Figure 4. a-GalCer treatment does not decrease effector CD8
+ T
cell population. Cells were stained with a combination of M45 and
M57 tetramers at day 7 post-infection. Percentages of tetramer positive
cells within CD8
+ T cell population (A, B). Absolute number of tetramer
positive CD8
+ T cells in each organ (C, D). *p-value#0.01.
doi:10.1371/journal.pone.0037991.g004
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cells [15,39,40,41]. These and other findings led to the develop-
ment of glycolipid analogs and strategies to polarize iNKT
responses [42,43,44,45] to better utilize iNKT properties in the
design of adjuvants or vaccines. In contrast to currently used
vaccine adjuvants, a-GalCer may be a viable adjuvant to boost
cellular responses as it has been show to enhance cellular immune
responses to malaria antigens when used as part of a DNA subunit
vaccine [8].
A variety of delivery methods have been examined including
pulsing dendritic cells with a-GalCer before administration [46] to
optimize the potential of a-GalCer. These methods are currently
being used in a variety of clinical trials in patients with advanced
cancer [47,48] but cannot be used in the context of vaccine
development against pathogens due to their complexity. In
addition, multiple injections of a-GalCer have been shown to
polarize immune responses and to induce iNKT anergy [49,50].
Another potential problem for using a-GalCer therapeutically is
that a-GalCer displays reduced effectiveness with time after
exposure to the pathogen [45]. We therefore decided to use a
simple method to test the effect of a-GalCer on the generation of
CD8
+ memory T cells during a well defined murine infection.
Our study showed that treatment with a-GalCer at the time of
infection did not affect acute CD8
+ effector T cell responses. This
is consistent with the fact that iNKT cells are dispensable in
controlling acute MCMV infection, and therefore should not
interfere with mounting an appropriate acute response [28,51].
Interestingly, as early at 48 hours post-infection, a-GalCer treated
mice exhibited decreased splenic and hepatic viral titers compared
with vehicle treated controls. Importantly however, a-GalCer
treatment did result in a larger MCMV-specific central memory
CD8
+ T cell compartment. Our results are consistent with a recent
paper, which shows that a-GalCer boosts memory CTL gener-
ation during flu vaccination [16]. In this context, Guillonneau and
colleagues found that a-GalCer promoted an increase in the
prosurvival gene Bcl-2 and increased long-term survival of
activated CD8
+ T cells [16]. In contrast to the previous study,
Bcl-2 levels were not elevated in activated CD8
+ T cells in the
MCMV system (Fig. S3).
During typical MCMV infection, IL-12 induced IFN-c peaks at
38 hours and other inflammatory cytokines and chemokines
including TNF-a, MIP-1a, MCP-1, and IL-6 are present in the
blood serum. a-GalCer treatment results in undetectable levels of
IL-12 at this time point and significantly decreases levels of other
pro-inflammatory signals. It has been determined that for CD8
+ T
cells to be fully activated and expand, they must respond not only
to antigen (signal 1) and co-stimulation (signal 2), but also to
‘‘signal 3’’ provided by type I interferon and IL-12 [52,53].
However, the same inflammatory cytokines promote terminal
differentiation and regulate CD8
+ T cell memory formation
through T-bet expression increase [6,32]. Our data suggest that
iNKT cell activation may modulate virus induced inflammatory
cytokine production to a sufficient level for signal 3 to be active yet
not reaching levels that promote terminal differentiation.
In conclusion, we have shown that a-GalCer treatment
enhances the immune response to viral infection, promoting
long-term immunity without disrupting the acute effector
response. We propose a model in which a-GalCer effects on both
the inflammatory response and viral titers drives the antigen CD8
+
T cell response toward memory differentiation. Interestingly in
patients with advanced cancer treated with a-GalCer an increase
in CMV specific memory CD8
+ T cells was observed [54]
suggesting that a-GalCer or an a-GalCer analog could also be
used therapeutically to control latent infection when the immune
system is impaired.
Figure 5. a-GalCer does not alter the overall number of MCMV
specific CD8
+ T cells in the spleen or liver. At 9 weeks post-
infection, cells were stained with M45 and M57 tetramers. Frequency of
tetramer positive cells in the spleen (A) or liver (B). Absolute number of
tetramer positive cells in the spleen (C) or liver (D). p-value=0.003.
doi:10.1371/journal.pone.0037991.g005
Figure 6. a-GalCer treatment increases the frequency and
number of MCMV specific central memory T cells in both
spleen and liver. Cells were stained with M45 and M57 tetramers.
Frequency of central memory CD8
+ T cells in spleen (A) and liver (B).
Absolute number of MCMV-specific central memory CD8
+ T cells in both
organs (C, D). *p-value,0.05.
doi:10.1371/journal.pone.0037991.g006
iNKT Cells Promote CD8
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Mice
C57BL/6 (Taconic Laboratory Animals and Services, German-
town, NY) were purchased for these studies. All mice were
maintained in pathogen free facilities at Brown University
(Providence, RI). All mice were between 6 and 10 weeks of age
at the time of infection.
Infection and treatment protocols
Stocks of MCMV clone RVG102 (a gift of Dr. Hamilton, Duke
University) recombinant for GFP under the Immediate early gene-
1 (ie-1) promoter [55] and American Type Culture Collection
(ATCC) Strain # VR1399
TM were prepared as previously
described from salivary glands [55]. Infections were on day 0
with 5610
4 (plaque forming units) PFU of MCMV delivered i.p.
a-GalCer (Avanti, Japan) or 100 mL vehicle (0.5% polysorbate-20)
was delivered 2 mg/mouse i.p. at the same time as MCMV
infection.
Isolation of lymphocytes and blood serum
To obtain splenic lymphocytes, spleens were minced, passed
through nylon mesh, layered on lympholyte-M (Cedarlane
Laboraties Ltd., Canada), harvested from the interface of the
gradient, and washed once in 1% PBS-serum. Hepatic lympho-
cytes were obtained by mincing and passage through a 70 mm
nylon cell strainer (Falcon, Franklin lakes, NJ). Cells were washed
3 times in 1% PBS-serum, and cell suspensions were layered on a
two-step discontinuous Percoll gradient (Pharmacia Fine Chem-
icals, Piscataway, NJ). Fat was removed and lymphocytes were
harvested from the interface of the gradient, and washed one time
in 1% PBS-Serum. Blood samples were collected by cardiac
puncture and spun at 14,000 rpm for 30 min at 4uC. Serum layer
was transferred to fresh tube.
Serum Cytokine Analysis
IFN-c, IL-4, IL-12p70, TNF-a, MCP-1 (CCL2), IL-6, IL-10,
IL-21, GM-CSF, IL-17A and MIP-1a (CCL3) were measured
using the cytometric bead array flex sets (BD Pharmingen) and
analyzed using FCAP Array Software. The following mAbs were
purchased from BD Pharmingen and used for ELISA: IFN-c
mAbs (clone R4-6A2, and clone XMG1.2), IL-4 mAbs (clone
4B11 and BVD6-24G2), and streptavidin-peroxidase. Sandwich
ELISA was performed as previously described [15].
Antibodies and reagents
TCRb-FITC, CD127-PerCP-Cy5.5, CD62L-PE-Cy7, CD3-
APC, CD44-AlexaFluor 750, and CD8-eFluor 450 were pur-
chased from eBioscience (San Diego, CA). M45 tetramer and M57
tetramer were obtained from the National Institute of Allergy and
Infectious Disease MHC Tetramer Core Facility at Emory
University (Atlanta, GA).
Flow cytometric analysis
Cells were resuspended in PBS buffer containing 1% FBS. Cells
were incubated with 2.4G2 mAb and stained with mAbs specific
for cell markers and tetramers for 15 min at 4uC. followed by
15 min at room temperature in the dark. Events were collected on
a FACSAria, and the data was analyzed using FlowJo (Tree Star
Inc.).
Determination of viral titers
Organ homogenates were made using the GentleMACS
(Miltenyi Biotek) RNA01 program. Standard plaque assay was
used to determine viral titers of the organs using MEF cells
(Jackson laboratories).
Statistical analysis
Statistical analysis was done using an unpaired Student’s t-test
except for Standard plaque assay for which a Mann-Whitney test
was performed. Significance was defined as p#0.05.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals as defined by the National Institutes of
Health (PHS Assurance #A3284-01). Animal protocols were
reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) of Brown University. All animals were
housed in a centralized and AAALAC-accredited research animal
facility that is fully staffed with trained husbandry, technical, and
veterinary personnel.
Supporting Information
Figure S1 MCMV-specific splenic CD8
+ T cells display
effector phenotype at 7 days post-infection with and
without a-GalCer treatment. Cells were stained with M45
and M57 tetramers in MCMV infected mice (A) and MCMV/a-
GalCer mice (B). Tetramer
+ cells were further characterized using
CD62L and KLRG1 (C, D).
(TIF)
Figure S2 a-GalCer treatment at the time of MCMV
infection increases the frequency of IL-7R
+ MCMV-
specific cells at 9 weeks post-infection. CD8
+ T cells from
mice infected with MCMV or mice treated with a-GalCer at the
time of infection were stained with M45 and M57 tetramers (A, B).
This population was further characterized with IL-7R (C, D) or
CD62L (E, F) and KLRG1.
(TIF)
Figure S3 a-GalCer treatment does not affect Bcl-2
expression on MCMV-specific CD8
+ T cells. CD8
+ T cells
from day 7 MCMV or MCMV/a-GalCer mice were stained with
M45 and M57 tetramers, permeabilized, and stained for
intracellular Bcl-2 expression. Bcl-2 levels were evaluated on
MCMV-specific CD8
+ T cells with and without a-GalCer
treatment. Isotype control is on whole CD8
+ T cell population.
(TIF)
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